What patent does Rezurock (rilzabrutinib) use?
Rezurock is the brand name for rilzabrutinib. Patent coverage for a drug like Rezurock typically includes multiple overlapping patent families (for example, composition-of-matter covering the active ingredient, and later patents covering specific formulations, methods of use, or additional compounds in the same chemical series). The exact patent numbers, assignees, and expiry dates depend on the country/jurisdiction and the specific “listed drug” or regulator record being referenced.
When do Rezurock patents expire?
Patent expiry dates vary by:
- Country (US vs. Europe vs. UK vs. Japan, etc.)
- Whether you mean the first composition-of-matter expiry or later “secondary” patents
- Patent term adjustments or extensions (where applicable)
- Regulatory exclusivities (which can extend market protection beyond patents)
To give a precise expiry date for “Rezurock patents,” you need the jurisdiction (e.g., US) and whether you want the earliest patent expiry, the last relevant patent expiry, or the regulator’s effective “no generic” date.
Is Rezurock protected by US patents, and when could generics enter?
In the US, generics and biosimilar competitors generally time entry around a mix of:
- Patent expiration for relevant Orange Book-listed patents, and
- FDA exclusivity periods that may delay approvals
A precise answer requires looking up Rezurock’s Orange Book record (and which specific patents are listed there), because the “last-to-expire” patent often controls when generic manufacturers can launch.
Who holds Rezurock’s patents?
Patent owners/assignees can include the original innovator and sometimes specific university or affiliate assignees tied to the underlying science. Ownership again depends on which country’s patent documents you’re looking at.
If you tell me the jurisdiction (US/EU/UK/etc.), I can narrow to the likely assignees and the relevant patent families for rilzabrutinib.
Are there patent challenges or litigation involving Rezurock?
For branded medicines, it’s common to see challenges around “listed” patents (for example, through generic patent challenges). Whether Rezurock has active litigation depends on the specific patents and the timeframe; this is also jurisdiction-dependent.
What’s the difference between patent expiry and market exclusivity for Rezurock?
Even after a patent expires, market entry can still be delayed by:
- Other unexpired patents that still cover the product
- Regulatory exclusivities recognized in that jurisdiction
So the first patent expiry date is not always the “first generic launch” date.
What I need from you to answer with exact patent numbers/dates
Reply with one of the following, and I’ll produce a targeted answer:
1) Which country/jurisdiction (US, EU, UK, etc.)?
2) Are you asking about the “earliest” patent expiry, the “last” relevant patent expiry, or the “generic launch” date?
3) If you’re looking at a specific patent or document, share the patent number or a link you’re working from.
Sources
No sources were provided in your prompt, and I don’t have enough information to look up exact Rezurock patent numbers/dates without the jurisdiction or a specific reference record.